Díaz RRM, Mendoza FME, Belmont PJ

Language: Spanish
References: 16
Page: 217-224
PDF size: 195.00 Kb.

ABSTRACT

Introduction: Therapeutic adherence (TA) in diabetes type 2 women were seen during pregnancy (DM2P), has proven to be a substantial element in decreasing maternal and perinatal morbi-mortality. At last were not exist specific instruments to value the AT in pregnancy diabetics.
Objective: To develop and validate a specific instrument to measure therapeutic adherence in diabetes type 2 women were seen during pregnancy (DM2P).
Material and Methods: A self administered instrument was designed to measure TA. It was submitted for review by multidisciplinary group of experts who assessed its logical and content validity to measure TA. The instrument was administered to 81 DM2P on two different days.
Results: After depuration of items, the instrumen had 25 closed items grouped in 6 domains: a)The knowledge that the patient has about the therapeutic regimen, b) the regularity in the medication, c) adherence to nutrition, d) attitude for the medication, e) asistance at the appointments, and f) if requieres emergency attention for the disease. The global rating of the questionnaire had a Crobach´s alpha of 0.9094. For the confiability evaluation we use variance analysis, and were not found statistical differences (F.005 p 0.946). For the validation we use the HbA_1c criterion like gold standar, founded that 40 (.77) of the patients with inadecuated adherence, have anormal contractions for this indicator (χ² = 4.239 p ≤ 0.3).
Conclusions: The questionnaire has logical validity, content validity and good level of consistency.

REFERENCES

1. Rull ZJA. Diabetes mellitus: complicaciones crónicas. México: Interamericana Mc-GrawHill; 1992.

2. UK Prospective Diabetes Study (UKPDS) Group: UK Prospective diabetes 16: Overview of 6 year´s therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58.

3. Norma Oficial Mexicana NOM-015-SSA21994. Para la prevención, tratamiento y control de la diabetes mellitus. Secretaría de Salud. Diario Oficial. Jueves 18 de julio de 2001.

4. Lerman G. Atención integral del paciente diabético. 2a. Ed. México: Interamericana McGraw-Hill; 1998.

5. Cox DJ, Gonder-Frederink L. Major developments in behavioral diabetes research. J Consult Clin Psychol 1992; 60: 628-38.

6. Anderson RM. Is the problem of the compliance all in our heads? Diabetes Educ 1985; 11: 31-4.

7. Adhrence to long-term therapies. Evidence for action. World Health Organization 2003.

8. Caldwell FR. An evaluation of a new patient compliance index using plasma propanol levels. J Chron Dis 1984; 37: 689-98.

9. Rico-Veridn B, Arriaga-Pérez MA, Gómez-Pérez JG, Campos-Aragón L, Escobedo de la Peña J. Prevalencia de diabetes mellitus y eficacia diagnóstica del programa de detección oportuna en una unidad de medicina familiar. Rev Med IMSS 1995; 33: 299-301.

10. López-Carmona JM, Ariza-Andrea RC, Rodríguez-Moctezuma JR, Murguía-Miranda C. Construcción y validación inicial de un instrumento para medir el estilo de vida en pacientes con diabetes mellitus tipo 2. Sal Pub Mex 2003; 45: 259-68.

11. Prieto L, Badia X. Cuestionarios de salud: concepto y metodología. Aten Primaria 2001; 28: 201-9.

12. Steiner DL, Norman GR. Health measurement scales. A practical guide to their development and use. 2nd. Ed. Nueva York (NY): Oxford University Press; 1995.

13. Feistein AR. Clinical Epidemiology. The architecture of clinical research. Philadelphia PA: W.B. Saunders Co.: 1985.

14. Litt IK, Cuskey WR. Satisfaction with health care: a predictor of adolescents appointment kepping. J Adol Health Care 1984; 5: 196-200.

15. Surwit R, Feinglos SM. Diabetes and behavior. A paradigm for health psychology. Am Psychol 1983; 3: 225-62.

16. Blackweell B. Treatment adherence. Br J Ppsych 1976; 129: 513-31.